Patient characteristics of 15 HLA-A2-positive AML patients
| Patient . | FAB subtype . | Time from diagnosis, mo . | Previous therapy . | Therapy at time of analysis . | Disease status at time of analysis . | T-cell response to WT1/proteinase 3 . | |
|---|---|---|---|---|---|---|---|
| ELISPOT . | IC IFN-γ . | ||||||
| 1 | M4 | 5 | araC/mit, araC/mit | None | CR1 | — | WT1 (both) |
| 2 | M3 | 48 | ATRA/araC, araC/dau | None | CR1 | WT1 (126) | WT1 (126) |
| 3 | M5* | 31 | PSC833, dau/araC, mit/eto | None | CR1 | — | WT1 (187) |
| 4 | M5 | 116 | Thio/araC/dau, araC/mit | None | CR1 | — | PR3 (169) |
| 5 | M2 | 62 | Thio/araC/dau, araC/mit | None | CR1 | — | — |
| 6 | M4 | 8 | Thio/araC/dau, araC/mit | araC/cyc | CR1 | — | NA |
| 7 | M4 | 18 | Thio/araC/dau, auto1 PBST, anti-CD33, araC/mit/eto | None | PR2 | — | — |
| 8 | M0 | 7 | araC/mit | araC/mit | Relapse | — | — |
| 9 | M6* | 9 | araC/mit, arsenictrioxid | None | Relapse | — | — |
| 10 | M5 | 4 | araC/mit | None | CR1 | PR3 (169) | PR3 (169) |
| 11 | M4 E0 | 2 | Thio/araC/dau, araC/mit | None | CR1 | — | — |
| 12 | M2 | 5 | Thio/araC/dau, araC/mit | Thio/araC | CR1 | PR3 (169) | PR3 (169) |
| 13 | M2* | 0 | None | None | Newly diagnosed | PR3 (169) | PR3 (169) |
| 14 | M6* | 0 | None | None | Newly diagnosed | WT1 (126) | NA |
| 15 | M4 E0 | 72 | araC, araC/eto | None | CR1 | — | NA |
| Patient . | FAB subtype . | Time from diagnosis, mo . | Previous therapy . | Therapy at time of analysis . | Disease status at time of analysis . | T-cell response to WT1/proteinase 3 . | |
|---|---|---|---|---|---|---|---|
| ELISPOT . | IC IFN-γ . | ||||||
| 1 | M4 | 5 | araC/mit, araC/mit | None | CR1 | — | WT1 (both) |
| 2 | M3 | 48 | ATRA/araC, araC/dau | None | CR1 | WT1 (126) | WT1 (126) |
| 3 | M5* | 31 | PSC833, dau/araC, mit/eto | None | CR1 | — | WT1 (187) |
| 4 | M5 | 116 | Thio/araC/dau, araC/mit | None | CR1 | — | PR3 (169) |
| 5 | M2 | 62 | Thio/araC/dau, araC/mit | None | CR1 | — | — |
| 6 | M4 | 8 | Thio/araC/dau, araC/mit | araC/cyc | CR1 | — | NA |
| 7 | M4 | 18 | Thio/araC/dau, auto1 PBST, anti-CD33, araC/mit/eto | None | PR2 | — | — |
| 8 | M0 | 7 | araC/mit | araC/mit | Relapse | — | — |
| 9 | M6* | 9 | araC/mit, arsenictrioxid | None | Relapse | — | — |
| 10 | M5 | 4 | araC/mit | None | CR1 | PR3 (169) | PR3 (169) |
| 11 | M4 E0 | 2 | Thio/araC/dau, araC/mit | None | CR1 | — | — |
| 12 | M2 | 5 | Thio/araC/dau, araC/mit | Thio/araC | CR1 | PR3 (169) | PR3 (169) |
| 13 | M2* | 0 | None | None | Newly diagnosed | PR3 (169) | PR3 (169) |
| 14 | M6* | 0 | None | None | Newly diagnosed | WT1 (126) | NA |
| 15 | M4 E0 | 72 | araC, araC/eto | None | CR1 | — | NA |
araC indicates cytosine-arabinoside; mit, mitoxantrone; ATRA, all-trans retinoic acid; dau, daunorubicin; eto, etoposide; thi, thioguanine; cyc, cyclophosphamide; CR1, first compete remission; PR2, second partial remission; and NA, not available.
Secondary AML.